Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon D Roger

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Nephrology (Carlton, Vic.)|August 8, 2006
Biosimilars: how similar or dissimilar are they?Simon D Roger
Nephrology (Carlton, Vic.)|October 4, 2006
Proton pump inhibitors: indigestion for nephrologists!Simon D Roger
The New England Journal of Medicine|March 6, 2007
Chronic kidney disease, anemia, and epoetinSimon D Roger
Expert Opinion on Biological Therapy|April 14, 2010
Biosimilars: current status and future directionsSimon D Roger
Clinical Kidney Journal|December 12, 2017
Practical considerations for iron therapy in the management of anaemia in patients with chronic kidney diseaseSimon D Roger
Nephrology (Carlton, Vic.)|March 21, 2007
Understanding epoetin use: databases or clinical trials?Simon D Roger
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 11, 2007
Epoetin trials: randomised controlled trials don't always mimic observational dataSimon D Roger, Adeera Levin
Nephrology (Carlton, Vic.)|September 15, 2004
What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?Simon D Roger, Bruce Cooper
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|August 31, 2007
Biosimilars: opportunity or cause for concern?Simon D Roger, Ashraf Mikhail
Kidney International|December 10, 2015
New data on the safety of IV iron-but why the discrepancy with FIND-CKD?Iain C Macdougall, Simon D Roger
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Nephrology (Carlton, Vic.)|August 8, 2006
Biosimilars: how similar or dissimilar are they?Simon D Roger
Nephrology (Carlton, Vic.)|October 4, 2006
Proton pump inhibitors: indigestion for nephrologists!Simon D Roger
The New England Journal of Medicine|March 6, 2007
Chronic kidney disease, anemia, and epoetinSimon D Roger
Expert Opinion on Biological Therapy|April 14, 2010
Biosimilars: current status and future directionsSimon D Roger
Clinical Kidney Journal|December 12, 2017
Practical considerations for iron therapy in the management of anaemia in patients with chronic kidney diseaseSimon D Roger
Nephrology (Carlton, Vic.)|March 21, 2007
Understanding epoetin use: databases or clinical trials?Simon D Roger
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 11, 2007
Epoetin trials: randomised controlled trials don't always mimic observational dataSimon D Roger, Adeera Levin
Nephrology (Carlton, Vic.)|September 15, 2004
What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?Simon D Roger, Bruce Cooper
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|August 31, 2007
Biosimilars: opportunity or cause for concern?Simon D Roger, Ashraf Mikhail
Kidney International|December 10, 2015
New data on the safety of IV iron-but why the discrepancy with FIND-CKD?Iain C Macdougall, Simon D Roger
Pageof 8